Cleveland BioLabs, Inc. (CBLI): Price and Financial Metrics
CBLI Price/Volume Stats
| Current price | $3.17 | 52-week high | $10.97 |
| Prev. close | $3.42 | 52-week low | $1.62 |
| Day low | $3.11 | Volume | 116,400 |
| Day high | $3.52 | Avg. volume | 271,922 |
| 50-day MA | $4.25 | Dividend yield | N/A |
| 200-day MA | $4.75 | Market Cap | 49.07M |
CBLI Stock Price Chart Interactive Chart >
Cleveland BioLabs, Inc. (CBLI) Company Bio
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.
Latest CBLI News From Around the Web
Below are the latest news stories about Cytocom Inc that investors may wish to consider to help them evaluate CBLI as an investment opportunity.
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via WebcastCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results conference call may be accessed from the "Investors" section of the Cytocom website at https://www.cytocom.com/investors/. The replay of the webcast will be archived on the website for 90 days beginning at approximately 10:00 a.m. ET, on August |
Cytocom, Inc. Reports Second Quarter 2021 Financial ResultsCytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, |
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance AgreementCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research. The agreement is directed to research that will support the development of potential new immune-modulating agents targeting toll |
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business ConferenceCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021. Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on |
Cytocom, Inc. to Report Second Quarter 2021 Financial ResultsCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m. ET, to discuss its corporate and financial results for the second quarter 2021. |
CBLI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 58.50% |
| 5-year | 56.16% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 473.09% |
| 2019 | -40.40% |
| 2018 | -74.81% |
Continue Researching CBLI
Want to do more research on Cleveland Biolabs Inc's stock and its price? Try the links below:Cleveland Biolabs Inc (CBLI) Stock Price | Nasdaq
Cleveland Biolabs Inc (CBLI) Stock Quote, History and News - Yahoo Finance
Cleveland Biolabs Inc (CBLI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...